A Neuroanatomic and Pathophysiologic Framework for Novel Pharmacological Approaches to the Treatment of Post-traumatic Stress Disorder.
Drugs February 1, 2024 Michael A Norred, Zachary D Zuschlag, Mark B Hamner 11 citations
PTSD is a debilitating disorder with complex underlying pathophysiology involving neurotransmitters, neurocircuitry, and neuroanatomical pathways. Only two SSRIs are currently FDA-approved for its treatment. The authors review novel and emerging treatments targeting non-serotonergic pathways, including drugs in development (BI 1358894, BNC-210, PRAX-114, JZP-150, LU AG06466, NYV-783, PH-94B, SRX246, TNX-102), established agents being investigated for PTSD (brexpiprazole, cannabidiol, doxasoin, ganaxolone, intranasal neuropeptide Y, intranasal oxytocin, tianeptine oxalate, verucerfont), and emerging psychedelic interventions (ketamine, MDMA-assisted psychotherapy, psilocybin-assisted psychotherapy). The aim is to integrate these agents into pathophysiological frameworks of trauma-related disorders.